Marksans aspires to become one of the most respected, profitable and integrated global pharmaceutical company that delivers international standards on all counts.
In order to achieve this objective, we have a special focus towards anticipating trends in the emerging markets (which hold the maximum potential), as well as reviewing the demands of the developed markets. Along with these focus markets, we are also trying to tap the Russian and CIS markets.
In the past few years, the company has achieved remarkable growth across markets. Starting with exports to emerging markets, the company has successfully penetrated into the regulated markets.
With the approval from the prestigious UK MHRA and US FDA, Marksans has actively started exporting formulation to UK and US. We have tied up with renowned players in these markets to aid distribution of OTC as well as prescription products.
Marksans has initiated dossier filling in the Russian and CIS markets. We are also registering our own dossiers, developing products going Off Patent and applying for registration of drugs that are shortly going Off Patent in the global markets.
Through contract manufacturing and active product registrations, Marksans is expanding its business across the rest of the European markets. We are focused towards formulation development and have a strong back up in terms of R&D and aggressive marketing plans.